Initiated Buy X

ARCT Arcturus Therapeutics

BTIG Research

$41

Initiated Outperform X

ARCT Arcturus Therapeutics

Leerink Partners

$70

Initiated Buy X

ARCT Arcturus Therapeutics

Canaccord Genuity

$90

Initiated Outperform X

ARCT Arcturus Therapeutics

William Blair

$71

Upgrades Neutral Buy X

ARCT Arcturus Therapeutics

H.C. Wainwright

$19 $51

Resumed Overweight X

ARCT Arcturus Therapeutics

Wells Fargo

$35

Downgrades Neutral Underperform X

ARCT Arcturus Therapeutics

Robert W. Baird

$18

Upgrades Neutral Buy X

ARCT Arcturus Therapeutics

Citigroup

$22 $35

Upgrades Underweight Eq Weight X

ARCT Arcturus Therapeutics

Barclays

$16 $25

Downgrades Mkt Perform Underperform X

ARCT Arcturus Therapeutics

Raymond James

Resumed Overweight X

ARCT Arcturus Therapeutics

Cantor Fitzgerald

$86 $39

Upgrades Underperform Neutral X

ARCT Arcturus Therapeutics

Robert W. Baird

$21 $18

Downgrades Buy Neutral X

ARCT Arcturus Therapeutics

Citigroup

$86 $29

Initiated Overweight X

ARCT Arcturus Therapeutics

Cantor Fitzgerald

$71

Resumed Neutral X

ARCT Arcturus Therapeutics

Goldman

$29

Downgrades Eq Weight Underweight X

ARCT Arcturus Therapeutics

Barclays

$33 $25

Resumed Neutral X

ARCT Arcturus Therapeutics

Robert W. Baird

$31

Downgrades Buy Neutral X

ARCT Arcturus Therapeutics

B. Riley Securities

$138 $77

Initiated Overweight X

ARCT Arcturus Therapeutics

Wells Fargo

$118

Downgrades Overweight Eq Weight X

ARCT Arcturus Therapeutics

Barclays

$46

Downgrades Buy Neutral X

ARCT Arcturus Therapeutics

H.C. Wainwright

Downgrades Outperform Mkt Perform X

ARCT Arcturus Therapeutics

Raymond James

Downgrades Outperform Neutral X

ARCT Arcturus Therapeutics

Robert W. Baird

$79 $69

Downgrades Buy Sell X

ARCT Arcturus Therapeutics

ROTH Capital

$77

Initiated Buy X

ARCT Arcturus Therapeutics

H.C. Wainwright

$15

Upgrades Buy Strong Buy X

ARCT Arcturus Therapeutics

WBB Securities

ARCT  Arcturus Therapeutics Ltd

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines